Sarcoidosis is a chronic, multisystem inflammatory disease of unknown etiology characterized by the formation of non-caseating (non-necrotizing) granulomas — compact collections of activated macrophages, epithelioid cells, and CD4+ T-lymphocytes — in virtually any organ of the body. The lungs and intrathoracic lymph nodes are involved in over 90% of cases, making sarcoidosis one of the most important differential diagnoses in interstitial lung disease. Other commonly affected organs include the skin, eyes, liver, spleen, heart, and brain. The etiology remains unclear, but current evidence supports a dysregulated immune response in genetically susceptible individuals triggered by an unidentified environmental antigen — possibly bacterial, viral, or particulate. The defining histopathologic feature is the non-caseating granuloma, which distinguishes sarcoidosis from tuberculosis (which produces caseating granulomas). Giant cells (Langhans type), Schaumann bodies (calcium-protein inclusions), and asteroid bodies may all be seen on biopsy. Clinically, sarcoidosis follows an unpredictable course — many patients experience spontaneous remission, while others develop chronic progressive disease leading to organ fibrosis. As an inpatient profee coder, sarcoidosis appears most often on pulmonary, cardiology, and neurology admissions; cardiac sarcoidosis (D86.85) in particular is an MCC in many DRGs and is frequently under-documented — always query the provider when cardiomyopathy or arrhythmia is present alongside a sarcoidosis diagnosis.
“A condition, process, or abnormal state” — a standard Greek suffix used to denote a pathological condition
The adjective sarcoid (meaning “resembling flesh, fleshy”) was first recorded in 1841, built from sarco- + -oid. Its use as a standalone noun followed by 1875. The full disease name sarcoidosis is attested in medical literature by 1936, following decades of separate clinical descriptions by Jonathan Hutchinson (1877, London — first reported cutaneous lesions), Ernest Besnier (1889, France — lupus pernio), and Jörgen Nilsen Schaumann (1915, Sweden — recognized it as a systemic disease). The word therefore literally translates as “a condition resembling flesh” — a reference to the pale, firm, flesh-colored granulomatous nodules that characterize the disease.
🔀 ALIASES / ALTERNATE TERMS
Sarcoid(shortened clinical term; also used as adjective, e.g., “sarcoid granuloma”)
Besnier-Boeck-Schaumann disease(historical eponym honoring the three primary describers)
Boeck’s sarcoid(older eponym from Norwegian dermatologist Caesar Boeck, 1899)
Pulmonary sarcoidosis(when lung is the dominant or only documented site)
C-reactive protein (CRP), high sensitivity (inflammatory marker)
⚠️ Coding Note:D86.9 (sarcoidosis, unspecified) should only be used when the documentation genuinely does not specify organ involvement — if the pulmonologist documents pulmonary sarcoidosis, code D86.0 or D86.2; don’t default to unspecified. D86.85 (sarcoid myocarditis) is a critical MCC — review every cardiology consult note when sarcoidosis is on the problem list, because cardiac involvement dramatically impacts DRG weight and is commonly undercoded. Multiple organ sites can and should be coded simultaneously (e.g., D86.0 + D86.83 + D86.85) when documented — this is NOT an Excludes situation. For profee inpatient, EBUS-TBNA (31652) is a high-value procedure code frequently performed for hilar/mediastinal node sampling in sarcoidosis workup; confirm the lymph node station sampled is documented in the procedure note. When hypercalcemia is documented as a complication of sarcoidosis, code E83.52 as an additional diagnosis — it’s a CC and should never be missed.
Crystal's MCW Coder Hub